Treated with CXCR4 antagonist AMD3100 significantly promoted colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 expressions, and also decreased colonic claudin-2 in colitis mice. Here, CLDN8 is linked to colitis.